Overview

Detailed Summary

Laurus Labs is a leading pharmaceutical and biotechnology company specializing in generic APIs and FDFs, with a strong focus on ARVs, oncology, and hepatitis treatments.
The company achieved a remarkable 30% revenue growth, reaching ₹5,001 crore, driven by strong performance in its CDMO and Generics divisions, demonstrating robust operational efficiency.
Significant capital investment occurred, with 15% of sales reinvested into expanding manufacturing capabilities, particularly in peptides and fermentation facilities.
Laurus Labs reported an impressive 388% increase in net profit for 9M FY26, attributed to improved product mix and operational leverage, leading to expanded EBITDA and gross margins.
The company is making strategic moves in biotechnology and advanced therapies, operationalizing gene therapy labs and actively investing in ADC capabilities, positioning itself in transformative health technologies.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 71,237 Cr
Volatility: Moderate Risk
P/E Ratio: 80.2
Industry P/E: 35.4
PEG Ratio: 3.5
P/B Ratio: 13.5
52W High: 1,140.90
52W Low: 573.20

Sales CAGR

1Y: 10.18%
3Y: 3.49%
5Y: 13.28%
10Y: 12.50%

Profit CAGR

1Y: 110.69%
3Y: -20.25%
5Y: 7.33%
10Y: 11.34%

ROE

TTM: 16.77%
3Y: 10.25%
5Y: 16.66%
10Y: 15.40%

ROCE

TTM: 16.14%
3Y: 14.69%
5Y: 20.73%
10Y: 19.96%

Technicals

‌

Forecasts

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
AUROPHARMA		1415.00	87,777 Cr	25.17	2.50	0.00	9.77	12.69	6.63
LAURUSLABS		1129.60	71,501 Cr	80.45	13.49	0.09	16.77	16.14	8.47
BIOCON		350.55	69,707 Cr	180.78	2.05	0.12	1.14	3.64	0.58
GLENMARK		2161.50	65,610 Cr	61.60	6.85	0.11	26.24	30.84	5.60
ALKEM		5605.20	65,584 Cr	27.66	4.91	0.82	17.69	18.13	11.95
ABBOTINDIA		26880.00	59,361 Cr	38.25	12.43	1.70	32.51	42.54	23.87
GLAXO		2482.00	41,331 Cr	39.90	18.23	2.34	45.69	61.23	23.96
Median: 7 Co.	—	2161.50	65,610 Cr	39.90	6.85	0.12	17.69	18.13	8.47

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	1,195	1,440	1,195	1,224	1,415	1,720	1,570	1,653	1,778	1,812
Expenses	1,014	1,198	1,024	1,045	1,130	1,300	1,187	1,250	1,298	1,299
Operating Profit	181	241	171	178	285	421	382	403	480	512
OPM %	15.18	16.77	14.33	14.57	20.15	24.45	24.35	24.39	27.00	28.27
Other Income	2.43	19	2.51	4.60	9.42	59	10	27	5.76	12
Interest	51	51	49	53	58	56	52	40	39	40
Depreciation	98	102	106	108	106	110	117	120	121	122
Profit Before Tax	35	107	18	23	131	312	224	270	327	361
Tax %	27.30	29.78	33.86	22.31	30.66	25.12	28.16	28.17	22.49	21.99
Net Profit	25	75	12	18	91	234	161	194	253	282
EPS in Rs	0.43	1.40	0.23	0.37	1.71	4.33	3.02	3.61	4.65	5.17

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	1,932	2,069	2,292	2,832	4,814	4,936	6,041	5,041	5,554	5,929
Expenses	1,497	1,643	1,936	2,267	3,263	3,513	4,448	4,263	4,499	4,662
Operating Profit	435	426	356	565	1,551	1,422	1,592	777	1,055	1,266
OPM %	22.50	20.60	15.53	19.94	32.22	28.82	26.36	15.42	19.00	21.36
Other Income	32	29	16	5.92	24	15	6.00	26	75	83
Interest	100	80	88	90	68	102	165	183	216	218
Depreciation	106	125	164	187	205	251	324	385	430	441
Profit Before Tax	234	237	120	294	1,301	1,084	1,109	236	484	690
Tax %	18.73	29.40	21.70	13.06	24.39	23.20	28.16	28.83	26.82	27.07
Net Profit	190	168	94	255	984	832	797	168	354	503
EPS in Rs	9.66	3.09	1.73	1.17	15.64	15.27	14.59	2.96	6.63	16.45
Dividend Payout %	7.22	9.52	17.05	52.19	10.94	13.03	13.66	26.94	18.07	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	16	106	106	106	107	107	107	108	108	108
Reserves	774	1,225	1,377	1,452	1,663	2,490	3,244	3,930	4,003	4,365
Borrowings	1,008	769	900	943	978	1,482	1,777	2,015	2,577	2,764
Other Liabilities	426	554	634	830	1,002	1,671	1,840	1,608	1,699	2,099
Total Liabilities	2,224	2,653	3,017	3,331	3,750	5,751	6,968	7,660	8,387	9,336
Fixed Assets	1,021	1,230	1,481	1,629	1,726	2,171	2,652	3,409	3,890	4,123
CWIP	70	143	163	110	67	362	813	551	423	458
Investments	7.05	3.41	3.41	3.41	3.41	3.41	31	50	124	233
Other Assets	1,126	1,277	1,369	1,589	1,953	3,214	3,472	3,651	3,950	4,521
Total Assets	2,224	2,653	3,017	3,331	3,750	5,751	6,968	7,660	8,387	9,336

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	182	332	342	298	347	733	911	994	666	602
Cash from Investing Activity	-312	-289	-384	-253	-221	-941	-914	-996	-822	-682
Cash from Financing Activity	103	-54	42	-45	-128	255	30	-27	250	39
Net Cash Flow	-27	-10	0.59	0.02	-1.37	47	27	-29	93	-41

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	27.20%	27.20%	27.19%	27.19%	27.18%	27.18%	27.60%	27.62%	27.59%	27.59%	27.49%	27.49%
FIIs	22.52%	24.03%	25.39%	25.97%	25.67%	26.08%	25.56%	25.52%	25.70%	26.16%	26.52%	25.82%
DIIs	10.35%	11.01%	11.14%	11.77%	13.56%	13.05%	12.74%	11.77%	11.94%	11.73%	12.43%	13.97%
Public	39.93%	37.76%	36.29%	35.07%	33.59%	33.69%	34.10%	35.09%	34.77%	34.51%	33.56%	32.71%
Total Shareholders	4,17,977	4,02,640	3,82,880	3,56,830	3,24,059	3,09,063	2,92,214	2,92,905	2,80,223	2,83,678	2,80,756	2,92,281

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY26

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Available on Pro Plan